Zusammenfassung
Es wird ein Patient mit chronischem Nierenversagen auf dem Boden einer malignen Hypertonie beschrieben. Durch Dialysebehandlung konnte die Hypertonie nicht beherrscht werden. Der orale Angiotensin-converting Enzym Hemmstoff Captopril (SQ 14.255; 2-D-methyl-3-mercaptopropanoyl-L-prolin) erzielte eine dramatische Senkung des Blutdrucks sowohl unter ambulanten Bedingungen, als auch während der Dialyse. Nach 6 monatiger Behandlungsdauer wurden keine unerwünschten Wirkungen beobachtet. Die Wirkung von Captopril kann als „biochemische Nephrektomie“ beschrieben werden.
Summary
A patient with end-stage renal disease due to malignant hypertension is described. Hypertension was resistant to hemodialysis. The orally active inhibitor of angiotensin-converting enzyme captopril (SQ 14.255; 2-D-methyl-3-mercaptopropanoyl-L-protein) dramatically lowered the elevated blood pressure both under ambulatory and dialysis conditions. No side effects were observed after 6 months' treatment. The effect of captopril could be described as a “biochemical nephrectomy”.
This is a preview of subscription content, log in via an institution to check access.
References
Vertes V, Cangiano JL, Berman LB, Gould A (1969) Hypertension in end-stage renal disease. N Engl J Med 280:978–982
Ondetti MA, Rubin B, Cushman DW (1977) Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196:441–445
Weber PC, Held E, Uhlich E, Eigler JOC (1975) Reaction constants of renin in juxtaglomerular apparatus and plasma renin activity after renal ischemia and hemorrhage. Kidney Int 7:331–338
Witzgall H, Hassan-Ali S (1980) Paper chromatographic systems for simultaneous separation of aldosterone, 18-hydroxycorticosterone, 18-hydroxydeoxycorticosterone, corticosterone, and deoxycorticosterone. J Chromatography (accepted for publication)
Vaughan ED, Carey RM, Ayers CR, Peach MJ (1979) Hemodialysis-Resistant Hypertension: Control with an Orally Active Inhibitor of Angiotensin-Converting Enzyme. J Clin Endocrinol Metab 48:869–871
Matthews PG, Johnston CJ (1979) Changes in endogenous circulating angiotensin and bradykinin after inhibition of converting enzyme (kininase II). Med J Aust [Spec Suppl] 2:12–15
Abe K, Itoh T, Satoh M, Haruyama T, Imai Y, Goto T, Satoh K, Otsuka Y, Yoshinaga K (1979) Indomethacin (IND) inhibits an enhanced renin release following the captopril, SQ 14225, administration. Life Sciences 26:561–565
Rommel AJ (1979) 14C-captopril elimination in patients with impaired renal function. Protocol 12, 928–18 from Squibb Research and Development 8176
Atlas SA, Case DB, Sealey JE, Laragh JH, Kinstry DN (1979) Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 3:274–280
Author information
Authors and Affiliations
Additional information
Supported by the Deutsche Forschungsgemeinschaft DFG Wi 548/1
Rights and permissions
About this article
Cite this article
Witzgall, H. Relief from malignant hypertension by treatment with captopril in a patient on maintenance hemodialysis. Klin Wochenschr 58, 871–873 (1980). https://doi.org/10.1007/BF01476998
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01476998